» Authors » Darshan H Brahmbhatt

Darshan H Brahmbhatt

Explore the profile of Darshan H Brahmbhatt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 153
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Brahmbhatt D, Scolari F, Fung N, Otsuki M, Lawler P, Ross H, et al.
ESC Heart Fail . 2025 Feb; PMID: 39925014
Aims: The inflammatory profile of cardiogenic shock (CS) after myocardial infarction affects outcomes; however, little is known about the impact of inflammatory changes in CS caused by acute decompensated heart...
2.
Brahmbhatt D, Kalra S, Luk A, Billia F
Can J Cardiol . 2025 Jan; PMID: 39798668
Patients with cardiogenic shock (CS) present with critical hemodynamic compromise with low cardiac output (CO) resulting in end-organ dysfunction. Prognosis is closely related to the severity of shock, and treatment...
3.
Wang V, Brahmbhatt D, Vishram-Nielsen J, Scolari F, Fung N, Otsuki M, et al.
CJC Open . 2024 Nov; 6(11):1342-1350. PMID: 39582696
Background: Cardiogenic shock (CS) is a complex, life-threatening condition that requires timely care of patients. The purpose of this study is to evaluate the characteristics and outcomes of patients transferred...
4.
Nielsen W, Szymanski M, Mirza K, van Laake L, Schmidt T, Brahmbhatt D, et al.
J Heart Lung Transplant . 2024 Oct; 44(2):236-245. PMID: 39426458
Background: Peak oxygen uptake (pVO) predicts mortality in patients with heart failure on left ventricular assist device (LVAD) support. This follow-up of the PRO-VAD study examines the prognostic value of...
5.
Colarusso L, Brahmbhatt D, Scolari F, Keon K, Shin E, De Pellegrin Overgaard A, et al.
ESC Heart Fail . 2024 Jun; 11(5):3023-3032. PMID: 38845185
Background: Cardiogenic shock (CS) is associated with high in-hospital mortality. Objective assessment of its severity and prognosis is paramount for timely therapeutic interventions. This study aimed to evaluate the efficacy...
6.
Brahmbhatt D, Ross H, OSullivan M, Artanian V, Mueller B, Runeckles K, et al.
JACC Heart Fail . 2024 Apr; 12(4):678-690. PMID: 38569821
Background: Guideline-directed medical therapy (GDMT) remains underutilized in patients with heart failure with reduced ejection fraction, leading to morbidity and mortality. Objectives: The Medly Titrate (Use of Telemonitoring to Facilitate...
7.
da Silveira A, Scolari F, Saadi M, Brahmbhatt D, Milani M, Milani J, et al.
Front Med (Lausanne) . 2024 Mar; 10:1289454. PMID: 38516229
Background: Persistent symptoms and exercise intolerance have been reported after COVID-19, even months after the acute disease. Although, the long-term impact on exercise capacity and health-related quality of life (HRQoL)...
8.
Rea A, Mihajlovic V, Vishram-Nielsen J, Brahmbhatt D, Scolari F, Wang V, et al.
Can J Cardiol . 2023 Dec; 40(4):664-673. PMID: 38092192
Background: Hemodynamic assessment for cardiogenic shock (CS) phenotyping in patients has led to renewed interest in the use of pulmonary artery catheters (PACs). Methods: We included patients admitted with CS...
9.
Rodenas-Alesina E, Brahmbhatt D, Mak S, Ross H, Luk A, Rao V, et al.
JACC Heart Fail . 2023 Oct; 12(1):16-27. PMID: 37804313
Left ventricular assist devices (LVADs) are increasingly used in patients with end-stage heart failure (HF). There is a significant risk of HF admissions and hemocompatibility-related adverse events that can be...
10.
Brahmbhatt D, Blitzer D, Billia F, Copeland H
Curr Opin Organ Transplant . 2023 Sep; 28(5):376-383. PMID: 37678172
Purpose Of Review: Heart transplant is the gold standard treatment for patients with end-stage heart failure, improving both quality of life and survival. Despite advances in donor and recipient management,...